Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (NASDAQ: LTRN) announced a virtual Key Opinion Leader (KOL) event on pancreatic cancer treatment featuring drug candidate LP-184. Scheduled for November 18, 2021, at 12:00 pm EST, the event will discuss LP-184's advances, a PTGR1-activated small molecule targeting genetically defined pancreatic cancer patients. Notable co-hosts include Dr. Igor Astsaturov, Dr. Ira Sharp, and Dr. Kishor G. Bhatia. Lantern's RADR® A.I. platform aims to transform oncology drug development. LP-184 has Orphan Drug Designation from the FDA for pancreatic cancer and glioblastoma.
Lantern Pharma (LTRN) announced its abstract on the efficacy of LP-184 in treating glioblastoma multiforme (GBM) has been accepted for virtual presentation at the Society for Neuro-Oncology 2021 Annual Meeting from November 18-21, 2021. The research indicates LP-184's effectiveness in both MGMT methylated and unmethylated GBM, particularly for those with DNA repair deficiencies. LP-184 has also received Orphan Drug Designation for malignant gliomas and pancreatic cancer. The findings support further development as a promising treatment for GBM.
On November 9, 2021, Lantern Pharma (NASDAQ: LTRN) announced its participation in two investor conferences. CEO Panna Sharma will present at the Q4 Investor Summit on November 16 at 11:00 am ET, available via webcast. CFO David Margrave will hold one-on-one meetings at the Torrey Hills Capital 6th Annual Emerging Growth Conference on November 17 in Rancho Santa Fe, California. Lantern Pharma focuses on oncology drug development using its RADR® A.I. platform, which identifies patients likely to respond to targeted therapeutics.
Lantern Pharma (LTRN) announced that its abstract on LP-284 has been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. This study focuses on LP-284's effectiveness in treating hematologic cancers. The drug shows promise as a synthetic analogue of LP-184, specifically targeting blood cancers. The poster presentation will occur on December 13, 2021, with Dr. Jianli Zhou as the presenter. Lantern aims to leverage its RADR® platform to optimize patient responses to its therapies.
Lantern Pharma (LTRN) reported significant advancements in its oncology pipeline and financial stability in its Q3 2021 update. The company boasts over $73.8 million in cash and marketable securities, a notable increase from $19.2 million at year-end 2020. Key highlights include the FDA granting Orphan Drug Designation for its LP-184 in glioblastoma and pancreatic cancer, as well as achieving over 10 billion data points in its RADR® AI platform.
Effective preclinical results for LP-184 were also shared, supporting further development and potential therapeutic collaborations.
Lantern Pharma (LTRN) announced that its RADR® A.I. platform has surpassed 10.4 billion datapoints, enhancing its capabilities in oncology drug discovery. This integrated platform offers mechanistic insights into drug-tumor interactions, optimizing drug development strategies and accelerating the identification of effective cancer therapies. Key advancements include new data sources from glioblastoma and pancreatic cancer, alongside improved algorithms to analyze complex datasets quickly. Lantern aims to leverage RADR® for innovative drug-candidate discoveries, ultimately seeking to improve clinical outcomes for cancer patients.
Lantern Pharma (LTRN) announced a collaboration with Code Ocean to enhance its oncology drug discovery efforts using AI. This partnership aims to leverage Code Ocean's Compute Capsule technology to improve the RADR® platform, making research more efficient. The integration focuses on data analysis, collaboration, and reproducibility, potentially reducing costs and development timelines. Lantern Pharma utilizes machine learning to develop therapeutics, currently working on four drug candidates. The collaboration supports partnerships with notable research institutions, optimizing research workflows and productivity.
Code Ocean has partnered with Lantern Pharma (LTRN) to enhance AI-driven computational research for oncology drug discovery. Leveraging Code Ocean's Compute Capsule technology, this collaboration aims to improve efficiency in development time and costs while increasing reproducibility. The integration will help Lantern Pharma utilize its extensive RADR® data points and collaborate effectively with research partners like the National Cancer Institute. This partnership is expected to accelerate the pace of drug discovery by providing a user-friendly and secure research platform.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced it will hold a conference call on November 1, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial and operating results. This conference aims to provide insights into the company's performance and upcoming milestones. Led by CEO Panna Sharma, the management team will also highlight the use of its RADR® A.I. platform for oncology drug discovery. Interested parties can register for the event via the company's website.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced its invitation to present at the Fall Harvest - Best Ideas from the Buy-Side conference, scheduled for October 5-8, 2021. CEO Panna Sharma will present on October 6 at 10:00 AM ET. The live webcast will be available for replay after the event. Lantern Pharma leverages its RADR A.I. platform to enhance oncology drug discovery, currently developing four drug candidates across eight tumor targets. Investors can register for the conference and schedule one-on-one meetings.